Induction of disease remission with one cycle of alemtuzumab in relapsing–remitting MS Academic Article uri icon

Overview

MeSH Major

  • Magnetic Resonance Imaging
  • Multiple Sclerosis
  • White Matter

abstract

  • Given that 96% of patients who did not relapse in the first 12 months following the initial dose of alemtuzumab remained relapse-free regardless of receiving a second course of drug, our data suggests that induction of disease remission for some patients might occur following just one dose of alemtuzumab. With further study, these data could support modification of the current therapy regimen.

publication date

  • April 17, 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00415-018-8845-4

PubMed ID

  • 29666985

Additional Document Info

start page

  • 1

end page

  • 4